FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893316500> ?p ?o ?g. }

• W2893316500 endingPage "5182" @default.
• W2893316500 startingPage "5174" @default.
• W2893316500 abstract "The purpose of this study was to establish the quality control and quantify the novel 64Cu-NOTA-Trastuzumab in gastric cancer patient-derived xenografts (PDX) mice models and patients by applying the molecular imaging technique. Trastuzumab was labeled with 64Cu using NCS-Bz-NOTA as bifunctional chelator, and hIgG1 was labeled with the same procedures as a negative control agent. HER2-positive (case 176, n = 12) and HER2-negative (case 168, n = 3) PDX models were established and validated by Western blot, DNA amplification, and immunohistochemistry (IHC). Both models were conducted for micro-PET imaging by tail injection of 18.5 MBq of 64Cu-NOTA-Trastuzumab or 64Cu-NOTA-hIgG1. Radioprobe uptake in tumor and main organs was quantified by region of interested (ROI) analysis of the micro-PET images and autoradiography. Finally, gastric cancer patients were enrolled in preliminary 64Cu-NOTA-Trastuzumab PET/CT scans. NOTA-Trastuzumab was efficiently radiolabeled with 64Cu over a 99% radiochemical purity and 17.5 GBq/μmol specific activity. The immune activity was preserved as the nonmodified antibody, and the radiopharmaceutical proved to be stable for up to 5 half-decay lives of 64Cu both in vitro and in vivo. Two serials of PDX gastric cancer models were successfully established: case 176 for HER2 positive and case 168 for HER2 negative. In micro-PET imaging studies, 64Cu-NOTA-Trastuzumab exhibits a significant higher tumor uptake (11.45 ± 0.42 ID%/g) compared with 64Cu-NOTA-IgG1 (3.25 ± 0.28 ID%/g, n = 5, p = 0.0004) at 36 h after intravenous injection. Lower level uptake of 64Cu-NOTA-Trastuzumab (6.35 ± 0.48 ID%/g) in HER2-negative PDX tumor models further confirmed specific binding of the radioprobe. Interestingly, the coinjection of 2.0 mg of Trastuzumab (15.52 ± 1.97 ID%/g) or 2.0 mg of hIgG1 (15.64 ± 3.54 ID%/g) increased the 64Cu-NOTA-Trastuzumab tumor uptake in PDX tumor (HER2+) models compared with 64Cu-NOTA-Trastuzumab alone ( p < 0.05) at 36 h postinjection. There were good correlations between micro-PET images and IHC ( n = 4) and autoradiography in PDX (HER2+) tumor tissues. Therefore, 64Cu-NOTA-Trastuzumab successfully translated to clinical PET imaging, and 64Cu-NOTA-Trastuzumab PET/CT scan in gastric cancer patients showed good detection ability. In conclusion, we reported quality control and application of novel 64Cu-NOTA-Trastuzumab for HER2 expression in PDX gastric cancer mice models and gastric cancer patients. Moreover, 64Cu-NOTA-Trastuzumab holds great potential for noninvasive PET detection, staging, and follow-up of HER2 expression in gastric cancer." @default.
• W2893316500 created "2018-10-05" @default.
• W2893316500 creator A5009072674 @default.
• W2893316500 creator A5023363049 @default.
• W2893316500 creator A5035364200 @default.
• W2893316500 creator A5048279362 @default.
• W2893316500 creator A5048800314 @default.
• W2893316500 creator A5050656056 @default.
• W2893316500 creator A5052913425 @default.
• W2893316500 creator A5059392900 @default.
• W2893316500 creator A5059589164 @default.
• W2893316500 creator A5061570382 @default.
• W2893316500 creator A5067981325 @default.
• W2893316500 date "2018-09-25" @default.
• W2893316500 modified "2023-10-16" @default.
• W2893316500 title "Noninvasive Detection of HER2 Expression in Gastric Cancer by ⁶⁴Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients" @default.
• W2893316500 cites W1514103999 @default.
• W2893316500 cites W1891860149 @default.
• W2893316500 cites W1915729010 @default.
• W2893316500 cites W1966850721 @default.
• W2893316500 cites W1978863320 @default.
• W2893316500 cites W2002897207 @default.
• W2893316500 cites W2037827070 @default.
• W2893316500 cites W2056839334 @default.
• W2893316500 cites W2073827381 @default.
• W2893316500 cites W2091164695 @default.
• W2893316500 cites W2105177613 @default.
• W2893316500 cites W2111965158 @default.
• W2893316500 cites W2114282952 @default.
• W2893316500 cites W2117646010 @default.
• W2893316500 cites W2117793816 @default.
• W2893316500 cites W2122147796 @default.
• W2893316500 cites W2122767481 @default.
• W2893316500 cites W2123276057 @default.
• W2893316500 cites W2130870133 @default.
• W2893316500 cites W2133105825 @default.
• W2893316500 cites W2144467667 @default.
• W2893316500 cites W2151425644 @default.
• W2893316500 cites W2151834271 @default.
• W2893316500 cites W2153565541 @default.
• W2893316500 cites W2168198903 @default.
• W2893316500 cites W2318605753 @default.
• W2893316500 cites W2532968325 @default.
• W2893316500 cites W2536233704 @default.
• W2893316500 cites W2556859315 @default.
• W2893316500 cites W2607481734 @default.
• W2893316500 cites W2694082842 @default.
• W2893316500 cites W2741631043 @default.
• W2893316500 cites W2804086091 @default.
• W2893316500 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00673" @default.
• W2893316500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30251865" @default.
• W2893316500 hasPublicationYear "2018" @default.
• W2893316500 type Work @default.
• W2893316500 sameAs 2893316500 @default.
• W2893316500 citedByCount "12" @default.
• W2893316500 countsByYear W28933165002019 @default.
• W2893316500 countsByYear W28933165002020 @default.
• W2893316500 countsByYear W28933165002021 @default.
• W2893316500 countsByYear W28933165002022 @default.
• W2893316500 countsByYear W28933165002023 @default.
• W2893316500 crossrefType "journal-article" @default.
• W2893316500 hasAuthorship W2893316500A5009072674 @default.
• W2893316500 hasAuthorship W2893316500A5023363049 @default.
• W2893316500 hasAuthorship W2893316500A5035364200 @default.
• W2893316500 hasAuthorship W2893316500A5048279362 @default.
• W2893316500 hasAuthorship W2893316500A5048800314 @default.
• W2893316500 hasAuthorship W2893316500A5050656056 @default.
• W2893316500 hasAuthorship W2893316500A5052913425 @default.
• W2893316500 hasAuthorship W2893316500A5059392900 @default.
• W2893316500 hasAuthorship W2893316500A5059589164 @default.
• W2893316500 hasAuthorship W2893316500A5061570382 @default.
• W2893316500 hasAuthorship W2893316500A5067981325 @default.
• W2893316500 hasConcept C121608353 @default.
• W2893316500 hasConcept C126322002 @default.
• W2893316500 hasConcept C142724271 @default.
• W2893316500 hasConcept C150903083 @default.
• W2893316500 hasConcept C159654299 @default.
• W2893316500 hasConcept C185592680 @default.
• W2893316500 hasConcept C203014093 @default.
• W2893316500 hasConcept C204232928 @default.
• W2893316500 hasConcept C207001950 @default.
• W2893316500 hasConcept C2779786085 @default.
• W2893316500 hasConcept C2989005 @default.
• W2893316500 hasConcept C502942594 @default.
• W2893316500 hasConcept C530470458 @default.
• W2893316500 hasConcept C71924100 @default.
• W2893316500 hasConcept C86803240 @default.
• W2893316500 hasConceptScore W2893316500C121608353 @default.
• W2893316500 hasConceptScore W2893316500C126322002 @default.
• W2893316500 hasConceptScore W2893316500C142724271 @default.
• W2893316500 hasConceptScore W2893316500C150903083 @default.
• W2893316500 hasConceptScore W2893316500C159654299 @default.
• W2893316500 hasConceptScore W2893316500C185592680 @default.
• W2893316500 hasConceptScore W2893316500C203014093 @default.
• W2893316500 hasConceptScore W2893316500C204232928 @default.
• W2893316500 hasConceptScore W2893316500C207001950 @default.
• W2893316500 hasConceptScore W2893316500C2779786085 @default.
• W2893316500 hasConceptScore W2893316500C2989005 @default.

• next